Investment Rating - The report maintains a positive investment rating for the pharmaceutical industry, focusing on domestic substitution opportunities and quality overseas targets [3]. Core Insights - The report emphasizes the ongoing focus on domestic substitution opportunities in the pharmaceutical sector, including scientific instruments, medical devices, blood products, medical consumables, and pharmaceutical packaging. It also highlights the recovery of domestic pharmaceutical consumption driven by policies related to traditional Chinese medicine and medical services [1][2]. Summary by Sections 1. CXO - The CXO sector is expected to see valuation recovery due to supportive policies for innovative drug development and a decrease in geopolitical risks [7]. 2. Innovative Drugs - The report notes a decline in the A-share chemical preparation sector by 7% and a 3.74% drop in other biological products, indicating market volatility [10]. 3. Traditional Chinese Medicine - The report suggests focusing on companies like China Resources Sanjiu, Yunnan Baiyao, and Tongrentang, as the market anticipates further consumption stimulus policies [18]. 4. Blood Products - The report highlights the strong pricing power of scarce resource manufacturers and the growing demand for immunoglobulin, suggesting a positive outlook for companies like Tian Tan Biology and Shanghai RAAS [21]. 5. Vaccines - The vaccine sector is under pressure, but there is potential for growth in specific areas such as HPV vaccines and other high-value products [23]. 6. Upstream Supply Chain - The report recommends focusing on companies with strong brand effects and overseas growth potential in the chemical and biological reagent sectors [26]. 7. IVD - The report indicates that the IVD industry is undergoing significant changes due to procurement policies, which may accelerate domestic substitution and increase market penetration [29]. 8. Medical Devices - The report suggests that the CGM market is expected to grow, particularly with the FDA approval of new products, indicating a positive outlook for companies like Sanofi [34]. 9. Medical Services - The report recommends focusing on eye and dental service companies, as well as traditional Chinese medicine services, in light of new consumption policies [39]. 10. Pharmacies - The report indicates that the pharmacy sector is stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [43]. 11. Raw Materials - The report notes that many raw material prices are stabilizing, suggesting potential investment opportunities in antibiotic intermediates and hormone raw materials [46]. 12. Innovative Instruments - The report emphasizes the potential for AI applications in the medical device sector, particularly in areas like surgical navigation and pathology screening [51]. 13. Low-value Consumables - The report highlights the potential for recovery in the low-value consumables sector, particularly for companies that can adapt to changing market conditions [60].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][22]. Core Views - The report highlights the dual focus on fertility support and health consumption, recommending attention to the medical services sector due to the expected benefits from new fertility policies and the aging population [2][12][22]. - The pharmaceutical industry is undergoing a digital transformation, with AI expected to significantly impact drug development, medical imaging, and healthcare services [3][34]. Summary by Sections Market Performance - The overall A-share market declined by 1.64%, with the biotechnology sector falling by 3.03%. The medical services sector experienced a drop of 5.99% [1][24]. Investment Strategy - The report suggests focusing on innovative drugs and medical devices, emphasizing the importance of high-quality research and development as the core driver of the industry [3][35]. - AI technology is identified as a key area for growth, with applications across various healthcare sectors [34][35]. Company Profit Forecasts and Ratings - Key companies such as Mindray Medical, United Imaging, and WuXi AppTec are rated as "Outperform," with projected net profits for 2023 ranging from 3.1 billion to 115.8 billion CNY [4][36]. - The report provides detailed profit forecasts for several companies, indicating a positive outlook for those with strong innovation capabilities [4][36]. Recommended Stocks - The report recommends several companies, including Mindray Medical, United Imaging, and WuXi AppTec, highlighting their strong market positions and growth potential [36][40]. - It also emphasizes the importance of companies involved in AI applications within healthcare, such as KingMed Diagnostics and BGI Genomics [35][36].

Core Viewpoint - The medical device industry is experiencing a transformation driven by AI, evolving from an efficiency tool to an "intelligent collaborator" [1][9][11] Group 1: AI Integration in Medical Devices - AI functionalities have become standard in medical devices showcased at the recent CMEF, indicating widespread adoption [2][8] - Major companies like GE Healthcare and Siemens have been intensively integrating AI into their products over the past few years [4][6] - The demand for AI in China's medical market is significant, with hospitals facing high patient volumes and a need for efficiency [5][6] Group 2: Efficiency and Workflow Improvements - AI applications have visibly improved efficiency in medical processes, such as reducing radiation therapy time from days to 24 minutes [6][9] - AI is helping to alleviate the workload of doctors, particularly in high-demand environments like China, where patient scans can exceed hundreds per day [6][9] - The integration of AI allows for enhanced image quality and diagnostic capabilities without the need for advanced hardware [7][9] Group 3: Challenges and Future Directions - Despite advancements, AI still faces challenges in data acquisition, learning capabilities, and the complexity of medical problems [1][11] - The industry is moving towards multi-modal diagnostics, integrating various data types for comprehensive health assessments [11][12] - Collaboration among device manufacturers and software companies is accelerating to address the challenges of diverse AI applications in healthcare [11][13] Group 4: Ecosystem Development - Companies are focusing on building digital ecosystems to enhance innovation and clinical application of AI technologies [14] - The emergence of platforms that integrate AI across various medical scenarios is being prioritized to streamline patient care and clinical workflows [12][13] - The competitive landscape is shifting from parameter-based competition to ecosystem collaboration and practical application of AI in healthcare [10][11]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Composite Index (000680) increased by 0.61% as of April 14, 2025, with notable gains from stocks such as Yuyuan Pharmaceutical (688658) up 19.91%, and Kexing Pharmaceutical (688136) up 16.90% [1] - The Penghua Sci-Tech Innovation Index ETF (589680) rose by 0.76%, marking its fifth consecutive increase, indicating a strong performance in the AI industry chain [2] - The top ten weighted stocks in the Sci-Tech Innovation Board Composite Index as of March 31, 2025, include Haiguang Information (688041) and Cambrian (688256), collectively accounting for 22.34% of the index [3] Group 2 - The AI industry chain is experiencing breakthroughs, with expectations for major product releases from companies like Alibaba and Tencent around May to June [2] - The Chinese government is likely to enhance policy support and funding for the technology sector, particularly in AI, as part of its strategy to counterbalance the U.S. in the ongoing trade disputes [2]

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Views - The report emphasizes the ongoing disruptions caused by the US-China tariff policies and suggests focusing on opportunities in non-US markets and import substitution [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, while companies primarily exporting to markets outside the US will be less affected [4][9] Summary by Sections Tariff Policy Overview - Since April 2, 2025, the US government has imposed a 34% "reciprocal tariff" on Chinese goods, with frequent adjustments to tariff rates and exemptions for certain pharmaceutical products [4][5] - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [5] Opportunities in the Biopharmaceutical Sector - The report identifies potential for domestic products to increase market share in the blood products sector due to tariff impacts, particularly for albumin, where US imports are significant [9] - It suggests monitoring companies such as Palin Bio, Tiantan Bio, and Huashan Bio for potential growth in market share as import costs rise [9] Medical Devices - The report notes that the tariff policies and anti-dumping investigations are likely to accelerate the domestic substitution process in medical devices, particularly in electrophysiology and imaging fields [10] - Companies like Yirui Technology and United Imaging are highlighted as making progress in domestic production capabilities [10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumption recovery" as key investment themes [12] - Specific companies to watch include BeiGene, Mindray, and Xiamen Innovax for their innovative products and overseas market potential [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, demonstrating strong cash flow and reduced losses [13][14] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products and a strong pipeline [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - **Wuxi Biologics**: Recognized for its strong technical capabilities and expanding overseas operations [22] Market Performance - The report notes a decline in the pharmaceutical sector, with a 5.61% drop in the past week, while the overall market saw a smaller decline [31][42] - The biopharmaceutical sector is highlighted as having the smallest decline among sub-sectors, indicating relative resilience [44]

Group 1 - The Shenwan Pharmaceutical Index declined by 5.61% this week, underperforming the CSI 300 Index which fell by 2.87%, ranking 22nd among 31 primary industry indices [1] - As of April 11, 2025, the price-to-earnings (PE) ratio for the pharmaceutical and biotechnology industry is 25.78 times, compared to 11.50 times for the CSI 300 Index, indicating a valuation premium of 124.23% for the pharmaceutical sector, which remains at a historical low [1] Group 2 - The recent changes in U.S. tariff policy, which exempt certain categories of goods from additional tariffs, are seen as a measure to ease U.S.-China trade tensions [2] - The exemption applies to all countries subject to "reciprocal tariffs," allowing products correctly classified under specified HTSUS numbers to benefit from a standard additional tariff of 10% instead of higher rates [2] Group 3 - The easing of tariff pressures is expected to benefit China's electronic and semiconductor supply chains, reflecting the strong competitiveness and cost-effectiveness of Chinese manufacturing [3] - The pharmaceutical industry in China also demonstrates similar supply chain capabilities, indicating a strong global reliance on China's pharmaceutical manufacturing, which reduces the likelihood of imposing high tariffs on drugs [3] Group 4 - The latest tariff policy significantly alleviates export chain pressures, with a focus on investment opportunities in the CXO, API, generic drugs, and medical device sectors [4] - Recommended companies include WuXi AppTec, WuXi Biologics, and others in the CXO chain, as well as Huahai Pharmaceutical and others in the API and generic drug sectors [4]

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Viewpoints - The ongoing US-China tariff policies are causing disruptions, suggesting a focus on non-US market expansion and import substitution opportunities in the biopharmaceutical sector [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, with companies primarily exporting to markets outside the US being less affected [4][9] - The report emphasizes the potential for domestic products to gain market share in the biopharmaceutical sector due to increased tariffs on US imports [9][10] Summary by Sections Tariff Policy Overview - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [4][5] Biopharmaceutical Sector Insights - The blood products sector is expected to stabilize prices and increase the market share of domestic products due to tariff impacts on imports, particularly for albumin [9] - The medical device sector is anticipated to accelerate domestic substitution due to reliance on North American production, with specific focus on electrophysiology and imaging products [10] - The report suggests monitoring companies such as Palin Bio, Tian Tan Bio, and Huashan Bio for potential growth opportunities in the blood products market [9][10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [12] - Specific companies highlighted for innovation include BeiGene, Dongcheng Pharmaceutical, and others with strong global competitiveness [12] - Companies like Mindray Medical and United Imaging are noted for their potential in overseas markets [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, showing a 49% year-on-year increase in sales [13] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - The report also highlights the potential of companies like East China Pharmaceutical and others in the nuclear medicine sector [17] Market Performance - The biopharmaceutical sector has seen a decline of 5.61% recently, with specific sub-sectors experiencing varying levels of impact [31][44]

Investment Rating - Industry investment rating: Outperform the market (expected to outperform the CSI 300 index by more than 5% in the next 6 months) [26] Core Insights - The medical device sector is experiencing a significant recovery in bidding activities, with a notable increase in procurement scale and project implementation since 2025. The demand that was previously suppressed is now being released, leading to a faster pace of project rollouts and bidding processes [3][4] - The procurement scale for new medical devices in December 2024 reached 27.7 billion yuan, a year-on-year increase of 60%. In January, February, and March 2025, the procurement scales were 17.36 billion yuan, 11.26 billion yuan, and 13.69 billion yuan, reflecting year-on-year increases of 41%, 77%, and 108% respectively [3][4][12] - Leading companies in the medical device sector are benefiting significantly from the recovery in bidding activities, with major players showing substantial year-on-year growth in procurement amounts [4][20] Summary by Sections Medical Device Update and Bidding Recovery - Medical device updates are intensively advancing, with significant bidding recovery observed. The projects are entering the implementation phase, and many provinces are starting to conduct centralized procurement [3][11] - The bidding scale for new medical devices has shown a marked improvement, with March 2025's bidding scale nearly returning to the levels seen in March 2023 [3][11] Procurement Scale and Growth Rates - In March 2025, the procurement scale for ultrasound reached 1.548 billion yuan (yoy +145%), CT at 2.037 billion yuan (yoy +140%), MRI at 3.520 billion yuan (yoy +138%), DR at 211 million yuan (yoy +124%), DSA at 650 million yuan (yoy +107%), and gastrointestinal endoscopes at 495 million yuan (yoy +142%) [4][12][16] Investment Recommendations - The report suggests focusing on leading companies that are enhancing their high-end and intelligent medical device layouts, such as Mindray Medical, United Imaging, KaiLi Medical, and Aohua Endoscopy. The 2025 government work report indicates increased funding support for key areas of equipment updates, which is expected to positively impact industry bidding growth [5][24]

Market Review - The overall performance of the pharmaceutical sector is currently at a low valuation, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The macroeconomic environment, including the recovery of US Treasury yields, is expected to positively influence the industry growth outlook for 2025 [8][9] - The CITIC Pharmaceutical Index fell by 5.42%, underperforming the CSI 300 Index by 2.54 percentage points, ranking 19th among 30 CITIC first-level industries [5][6] Stock Performance - The top ten stocks with the highest gains this week include Jinhe Biology, Yirui Technology, and Yipinhong, with gains ranging from 12.69% to 20.54% [4][5] - The top ten stocks with the largest declines include Rundu Co., Duorikang Pharmaceutical, and Boteng Co., with declines ranging from 27.21% to 27.81% [4][5] Investment Themes - **Innovative Drugs**: The domestic innovative drug sector is transitioning from quantity to quality, focusing on differentiated and internationalized pipelines. Companies expected to deliver profits include Hengrui, Baiji, and Betta [8] - **Medical Devices**: The bidding volume for imaging equipment has significantly rebounded this year, with ongoing equipment updates. Companies like Mindray and United Imaging are highlighted for their growth potential [8] - **CXO and Life Science Services**: The investment environment is expected to improve, with a recovery in demand for life science services. Companies in this sector are anticipated to experience high profit elasticity as they enter the return phase [8] - **Pharmaceutical Industry**: The specialty API sector is expected to see cost improvements, with valuations at a near ten-year low, indicating a new growth cycle. Companies like Tonghua Dongbao and Huahai Pharmaceutical are recommended for attention [8] Industry Outlook - **Traditional Chinese Medicine**: The market for essential medicines is expected to see growth, particularly for unique products. Companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical are recommended [10] - **Pharmacy Sector**: The prescription outflow and market optimization are expected to enhance the pharmacy sector's investment opportunities, with companies like YaoBai and YiFeng Pharmacy highlighted [10] - **Medical Services**: The anti-corruption measures and centralized procurement are expected to improve the market environment for private medical services, with companies like Guoshengtang and Aier Eye Hospital recommended [10] Financial Performance - **CRL**: In 2024, CRL's revenue was $4.05 billion, a 1.9% decline year-on-year, with a significant drop in net profit due to goodwill impairment [14] - **Labcorp**: Labcorp's 2024 revenue reached $13.01 billion, a 7% increase year-on-year, with a net profit of $746 million, reflecting strong growth in diagnostic laboratory services [23][31] - **IQVIA**: IQVIA reported a 2.8% increase in revenue for 2024, reaching $15.40 billion, with a net profit of $2.04 billion, driven by strong performance in its TAS segment [38][39] Company-Specific Insights - **Medpace**: Medpace's 2024 revenue was $2.11 billion, a growth of 11.8%, with a net profit of $404 million, indicating strong performance driven by small and mid-sized pharmaceutical companies [58] - **Lonza**: Lonza's 2024 revenue was 6.57 billion Swiss Francs, with strong demand in the commercial phase and a recovery in early-stage biopharmaceuticals [80][81]

证券研究报告 | 医药生物 | 2025年4月12日 www.hczq.com 华创医药投资观点&研究专题周周谈·第121期 海外CXO 2024财报总结 本周周专题联系人：万梦蝶 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.com | | 医疗器械组组长 李婵娟 | 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 高初蕾 | 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com | | 分析师 万梦蝶 | 执业编号: S0360523080008 邮箱: wanmengdie@hcyjs.com | | 分析师 王宏雨 | 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com | | 分析师 朱珂琛 | 执业编号：S0360524070007 邮箱 ...